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Objectives: A review is made of the clinical, diagnostic, therapeutic and survival characteristics of Ewing sarcoma 
(ES) of the oral cavity.
Material and Methods: A systematic literature search was carried out, with restrictions referred to time (1960-
2014), language (English and Spanish) and type of study (case reports, letters, datasets, reviews). The following 
MeSH terms and boolean operators were used: Ewing AND Sarcoma AND [tongue, jaw, maxilla, cheek, condyle 
OR temporomandibular, floor AND mouth, gum OR gingiva, palate OR palatal, lip, uvula, head AND neck].
Results: Seventy-one cases of ES of the oral cavity were documented from 53 articles. The main differences versus 
ES of other locations were a younger age at manifestation, a shorter time from symptoms onset to diagnosis, and 
swelling as the most frequent clinical manifestation versus swelling and pain in the rest of disease locations. The 
way in which ES manifests in the oral cavity is varied and comprises dental displacement (19.7%), dental mobility 
(7%), root reabsorption (5.6%), destruction of the dental follicle (4.2%), premature exfoliation (4.2%) and pares-
thesia of the chin (2.8%). Metastatic neck adenopathies appear in 11.3% of the cases. Significant differences in sur-
vival are observed between patients with a complete diagnosis of ES (hematoxylin-eosin staining, PAS positivity, 
CD99 positivity) and those with an incomplete diagnosis.
Conclusions: Ewing sarcoma of the oral cavity presents a series of specific features that distinguish it from ES of 
other locations.




Ewing sarcoma (ES) was first described in 1921 by Ja-
mes Ewing, who referred to the disease as diffuse en-
dothelioma of bone, because he assumed that the tumor 
originated from the vascular component of bone. Since 
then the disease has received a number of names: pe-
rithelioma, endothelial myeloma, reticuloendothelioma, 
reticular sarcoma and intramedullary sarcoma - thus 
evidencing the uncertainty regarding the true origin of 
the tumor. In 1928, Oberling proposed the term Ewing 
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sarcoma, thereby obviating the debate about the causal 
cells. The designation proposed by the World Health Or-
ganization (WHO) is Ewing sarcoma/primitive neuroec-
todermal tumor (ES/PNET), based on the assumption 
that both entities correspond to the same process, sin-
ce they share the same genetic alteration (translocation 
11:22) in over 95% of the cases (1).
The origin of ES remains unclear, though the tumor is 
suspected to derive from the neuroectodermal cells. The 
immature reticular cells and primitive mesenchymal 
cells of the bone marrow (2) have also been proposed as 
possible origins of the tumor.
Ewing sarcoma is the fourth most common bone malig-
nancy after myeloma, osteosarcoma and chondrosarco-
ma (though some authors rank it ahead of chondrosar-
coma) (3), and it is the second most frequent malignant 
bone tumor in infancy and childhood, after osteosarcoma 
(4) - with an estimated incidence of 2.93 cases/million 
inhabitants under 20 years of age/year (5). Ewing sarco-
ma represents 1% of all malignant tumors in children (6) 
and between 4-10% of all bone malignancies (7). Its be-
havior is that of an aggressive malignant tumor, and it has 
been estimated that metastases are already present at the 
time of diagnosis in 15-28% of the cases (6,8). However, 
when occult micrometastases are considered, some publi-
cations raise this percentage to as high as 80% (9). The 
tumor shows a predilection for the male gender in 2.1-2
.4:1 proportion (5,9), and it is 10 times more frequent in 
Caucasian children than in black children (10).
Hematoxylin-eosin staining (HE) defines ES as belon-
ging to the group of small blue round cell tumors - a 
series of very aggressive tumors with a high incidence 
in children and adolescents. The periodic acid-Schiff 
technique (PAS), which stains carbohydrates red, is 
usually positive in ES, revealing the presence of intra-
cellular glycogen granules, which help differentiate the 
disease from tumors of neural lineage. Ewing sarcoma 
is also positive for cluster of differentiation 99 (CD99), 
a protein encoded for by the myc2 gene located on the 
short arm of chromosomes X and Y, and which is highly 
sensitive for small blue round cell tumors in children, 
particularly ES/PNET, lymphoblastic lymphoma and 
lymphoblastic leukemia.
The most precise diagnostic factor is translocation 
t(11;22)(q24;q12), which is detected in 85-90% of all 
cases of ES (9). This translocation gives rise to a fusion 
gene called EWS/FLI1 (Ewing Sarcoma/Friend leuke-
mia integration 1 transcription factor). In approximately 
5% of all cases, the EWS gene is implicated in other 
types of translocations, namely t(21;22)(q12;q12) and 
t(7;22)(p22;q12), which give rise to the fusion genes 
EWS-ERG and EWS-ETV1, respectively (11). One-
fourth of the tumors present p16 and p53 alterations, 
which is associated to more aggressive behavior of the 
disease and a poorer response to chemotherapy (12).
The most frequent location of ES is in the long bones 
(58%), pelvis (20%) and ribs (7%) (7). Ewing sarcoma 
of the head and neck is less common, representing about 
3% of all cases (13,14). It accounts for 10.5% of all pri-
mary malignancies of the mandible (11). Ewing sarcoma 
of the oral cavity has a series of particularities which are 
addressed in the present study.
The tumor is still associated to a poor prognosis, though 
the latter has improved considerably as a result of the 
introduction of recent treatment protocols warranted by 
clinical trials. Treatment initially consisted of radiothera-
py and surgery, and was associated to a very poor survi-
val rate of about 20% after three years (15) and of 5-8% 
after 5 years (10). The studies of Rosen et al. (16), ad-
ministering neoadjuvant chemotherapy, radically chan-
ged the prognosis of the disease. Current management 
is based on neoadjuvant chemotherapy, surgery / radio-
therapy, and adjuvant chemotherapy. With this strategy, 
overall survival currently varies between 59% and 81% 
after three years, according to whether adults or children 
are involved, and the disease-free survival rate is about 
60% after 5 years (17,18). This percentage decreases to 
30% after 3-5 years in the case of disseminated disease 
at the time of diagnosis (19,20).
The present study analyzes the available clinical infor-
mation of ES of the oral cavity.
Material and Methods
A structured Medline search was made with the fo-
llowing restrictions and search sequences:
Time restriction: 1 January 1960 to 30 June 2014.
Language restriction: English and Spanish.
Publication restriction: human, case reports, letters, da-
tasets, reviews.
The following MeSH terms and boolean operators were 
used:
Ewing AND Sarcoma AND [tongue, jaw, maxilla, 
cheek, condyle OR temporomandibular, floor AND 
mouth, gum OR gingiva, palate OR palatal, lip, uvula, 
head AND neck].
A total of 297 literature references were identified. After 
manually filtering the articles found to be duplicated in 
the different search strategies and those that lacked cli-
nical information, a total of 53 publications were finally 
selected. Of these, 45 corresponded to a case description, 
while two, three, two and one article reported 2, 3, 4 and 
5 clinical cases, respectively. A total of 71 clinical cases 
of ES of the oral cavity were compiled. The following 
information was collected for each case, where avai-
lable: patient gender, age, tumor location, time to first 
consultation, personal history, initial diagnostic impres-
sion, first manifestation of the disease, other subsequent 
clinical manifestations, imaging findings (conventional 
X-rays, panoramic X-rays, computed tomography [CT], 
magnetic resonance imaging [MRI], etc.), metastases 
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and the technique used to diagnose metastatic spread, 
treatment provided, and survival.
A descriptive analysis was made, with frequency dis-
tributions for qualitative variables and calculation of 
the mean and standard deviation (SD) (with the corres-
ponding confidence interval) in the case of quantitative 
variables. Survival curve was plotted using the Kaplan-
Meyer method. Lastly, the data of the present study were 
contrasted with the historical information referred to ES 
of systemic and craniofacial location.
Results
The documented cases were published in 53 articles in 
29 different journals. The great majority of the publi-
cations (45/71; 63.4%) corresponded to single clinical 
cases. The journal with the largest number of published 
cases was Oral Surg Oral Med Oral Pathol Oral Radiol 
(11 cases), followed by J Craniofac Surg (8 cases) and 
Otolaryngol Head and Neck Surg (7 cases).
A little over one-half of the cases were published in buc-
codental journals (56.3%), while the rest were published 
in general medical journals or journals corresponding to 
other specialties (Oncology, Otorhinolaryngology, Ra-
diology, etc.).
Although the study design contemplated data compila-
tion starting in the year 1960, most of the cases were of 
recent publication. Over one half (56.3%) were publis-
hed in the period 2000-2014, while less than one-fifth 
were published between 1960-1990 (19.7%).
Ewing sarcoma of the oral cavity showed a slight female 
predominance (50.7%), with a mean patient age of 15 
years and 3 months ± 8 years and 7 months (SD) (ran-
ge: 1-43 years). The tumor was fundamentally located in 
the mandible (69% of the cases). The first clinical ma-
nifestation was swelling (46.5%), followed by swelling 
and pain (12.7%). One out of every 5 cases (21.1%) was 
initially mistaken for dental infection. In descending 
order of frequency, the disease clinically manifested in 
the form of swelling (70.4%), pain (28.2%), dental dis-
placement (19.7%), neck adenopathies (11.3%), fever 
(9.9%), dental mobility (7%), root reabsorption (5.6%), 
destruction of the dental follicle and premature dental 
exfoliation (4.2%). Ewing sarcoma was predominantly 
of hard consistency (29.6%), and the overlying mucosa 
was usually of normal appearance (15.5%). The imaging 
techniques characteristically revealed a radiotransparent 
lesion (38%) with poorly defined limits (40.8%). Table 
1 describes the most relevant clinical data compiled in 
our study.
In 31% of the cases no description was provided about 
the diagnostic methods used. In 18.3% of the patients 
the diagnosis was established from HE and PAS stai-
ning, CD99 and the translocation 11:22 study findings. 
In 8.5% of the cases HE and PAS staining and CD99 
were used, while in 11.3% of the patients only HE and 
PAS staining were employed. The histopathological cri-
teria leading to the diagnosis of ES of the oral cavity in 
each case are summarized in figure 1.
The most common management strategy was chemothe-
rapy and surgery, followed by chemotherapy and radio-
therapy. The different treatment modalities are described 
in figure 2.
Table 2 and figures 3a and 3b show the survival data of 
the patients with ES of the oral cavity, with the corres-
ponding gender comparison.
The size of the tumor at the time of diagnosis was repor-
ted in 26 cases (36.7%). Seventeen of them mentioned 
the clinical size of the lesion, while 6, 1 and 2 assessed 
lesion size from the CT scan, MRI study and measure-
ment of the surgical piece, respectively. The most com-
mon tumor size was 3-5 cm in diameter (in 15 of the 26 
cases for which information was available; 57.7%), with 
a range of 1-12 cm.
Of the total 71 cases, 6 (8.5%) corresponded to oral me-
tastatic spread of a primary tumor in some other location, 
and in one case (published in 1968 (21)) the primary or 
metastatic nature of the lesion could not be established 
from the description of the clinical case. The remaining 
64 tumors corresponded to primary malignancies of the 
oral cavity. Most of the publications either failed to spe-
cify whether metastatic disease was present or simply 
stated that there was no metastatic spread, without ex-
plaining how this was confirmed (33/64; 51.6%). In tho-
se cases where such information was provided, metas-
tatic X-ray series, CT and scintigraphy (with or without 
bone marrow biopsy) were the most commonly used 
techniques (Table 3).
Discussion
Overall, Ewing sarcoma is more prevalent in males than 
in females when considering all tumor locations. Some 
publications specifically referred to the head and neck 
report a male predominance of between 1.4:1 (22) and 
2.4:1 (5). This gender difference is not seen in ES of 
the oral cavity and appendages, where the gender dis-
tribution appears to be balanced, with only a very slight 
female predominance of 1:1.05 (Table 1). Some authors 
comment that the gender difference is noted above the 
age of 13 years (23). However, the data obtained in our 
study indicate otherwise, with a slightly greater predo-
minance in females among patients over 13 years of age 
(1:1.25).
Patient age at onset of the disease (mean: 15 years and 3 
months ± 8 years and 7 months; median: 14 years) was 
lower than reported for ES of any location (18 years) 
(17). With regard to ES of the oral cavity, our data co-
incide with those reported by other series (11,24), but 
differ clearly from the findings of Gupta et al. (10), who 
reported a mean patient age for head and neck locations 
of 10.9 years. The published data correspond to case se-
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Gender 47,7% males; 50,7% females; 1,4% not specified
Age at onset of the disease Mean; 15 years and 3 months. Median: 14 years. Range: 1-43 years
Lapse time until first medical 
consultation
Mean: 5  months and 12 days. Median: 2 months
Location Mandible: 69%; Maxilla: 28,2%. Soft tissues: 2,8%
Origin Primary: 73,2%; Metastatic: 8,5%; Uncertain: 2,8%. NIA: 15,5%
First clinical manifestation Swelling: 46,5%. Swelling and pain: 12,7%. Pain: 5,6%; Paresthesia: 2,8%. 
Others: 15,1%*; NIA: 18,3%
*Fever, dental mobility, facial asymmetry and other associations.
Initial diagnostic suspicion Dental infection: 21,1%. Parotitis: 4,2%. Dental eruption disturbances: 
2,8%. Benign tumor or disease: 2,8%. Benign nasal disease: 2,8%. Burkitt’s 
lymphoma: 1,4%. IND:64,9%
Clinical manifestations Yes No
    Swelling 70,4% 7,0%
    Pain 28,2% 43,7%
    Fever 9.9% 40.8%
    Neck lymphadenopathies 11.3% 35.2%
    Dental displacement 19.7% 21.1%
    Other dental disturbances Destruction of dental follicle: 4,2%. Premature dental exfoliation: 4,2%. 
Dental mobility: 7%. Root resorption: 5,6%
   Palpation Firm: 29,6%; elastic: 2,8%; soft: 9,9%; NIA: 57,5%
  Overlying mucosa Normal: 15,5%; erythematous: 8,5%; ulcerated: 4,2%; other: 2,8%. NIA: 
69%
Imaging (density) Radiotransparent: 38%; mixed: 9,9%; radiopacity: 4,7%; NIA: 49,4%
Imaging (limits) Poorly defined: 40,8%; Well defined: 5,6%; NIA 53,5%
NIA: No Information Available
Table 1. Manifestations of Ewing Sarcoma of the oral cavity.
Fig. 1. Histological criteria employed for diagnosis of Ewing 
Sarcoma on clinical cases analyzed (H-E: hematoxylin-eosin; 
CD99: Cluster of Differentiation 99; PAS: Periodic acid-Schiff 
technique. Translocation study: translocation study 11,22).
Fig. 2. Management strategies described in Ewing Sarcoma of the 
oral cavity.
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(expressed in months) Mean 95% CI Median 95% CI
Male 58.9 35.3-82.4 36 4.2-67.8
Female 77.3 28.6-126 48 25.8-70.2
Overall 72.6 39.3-105.9 40 26.9-53.1
Table 2. Survival of Ewing sarcoma. Mean and median with confidence interval (95% CI).
Fig. 3. Survival analysis based on Kaplan-Meyer method in Ewing Sarcoma of the oral cavity. Compari-
son between genders.
ries involving very few patients, and this could explain 
the broad variability observed. Our data also confirm the 
accumulation of most cases (83.1%) in the 5-25 years 
age range, as already reported for ES of any location 
(6).
The time from first clinical manifestation of the disease 
to first medical consultation was reported in almost two-
thirds of the cases (63.3%), and ranged widely (mean: 
5 months and 12 days ± 8 months; range: 1-48 mon-
ths). We therefore consider reporting of the median to 
be clinically more useful (2 months). This delay in first 
consultation is slightly shorter than in other malignan-
cies of the oral cavity (25), and this may be related to 
the rapid and aggressive growth of the tumor, and the 
fact that it commonly manifest in children, which are 
usually monitored more closely. The mentioned delay is 
also slightly shorter than that reported for ES of other 
locations (26), probably because of the greater visibility 
and accessibility of tumors of the oral cavity. A relation-
ship has been described between tumor location in the 
pelvis, legs and arms and a longer time in establishing 
the diagnosis (27).
The mandible was the most frequent location of the tu-
mor in both our study limited to the oral cavity and in 
studies involving the head and neck - representing over 
two-thirds of all the lesions (68%). Our observation co-
incides with that of Gupta et al. (10), who in a series 
of 65 cases of primary sarcoma of the jaws recorded a 
mandibular location in 70.7% of the cases, with a pre-
dilection for the ascending ramus (28,29). It has been 
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Table 3. Diagnostic procedures for metastasis detection in Ewing Sarcoma. 
Diagnostic procedure Number of cases 
(N=64)
Without information 18
Without metastasis but without information about the 
procedure
15
Computed Tomography (CT) 5
Scintigraphy 7
Scintigraphy and bone marrow biopsy (BMB) 4
Metastatic X-ray series 7
Metastatic X-ray series and BMB 1




suggested that the larger amount of bone marrow present 
in the ascending ramus would account for the greater 
prevalence of these tumors in that location (30).
Despite the strong tendency of these tumors to produce 
distant metastases, only 8.5% of the documented cases 
were oral metastases of primary tumors in other loca-
tions. This is consistent with the observations of other 
publications that have found approximately 90% of the 
mandibular malignancies to be primary tumors (28,31). 
In most of the metastatic presentations, the primary tu-
mor was located in the ribs (66.6%).
It is accepted that the most frequent initial manifesta-
tion of the disease is in the form of swelling and pain, 
though in our study specifically centered on ES of the 
oral cavity the most frequent initial manifestation was 
swelling only. This was the case in one-half of the pa-
tients (46.5%), while the combination of swelling and 
pain as first manifestation of the disease was only recor-
ded in a little over one of every 10 cases (12.7%). The 
oral cavity is easily accessible to exploration, and the 
bone structures do not lie under thick muscle layers as in 
other more common locations of ES such as the femur, 
pelvis or even the ribs. This may explain why tumors in 
these locations are identified later than tumors of the oral 
cavity, and consequently why pain is more often repor-
ted as first manifestation, whether associated to swelling 
or not (26).
Ewing sarcoma of the oral cavity has relevant features 
not found in other locations, and which are relevant for 
the dental surgeon, such as initial manifestation of the 
disease with mental nerve paresthesia, dental displace-
ment, or dental mobility (Table 1).
Information referred to the initially suspected diagnosis 
was only available in one of every three cases (35.1%), 
though it is interesting to note that the tumor was ini-
tially managed as a dental infection in 21.1% of the pa-
tients. It may be postulated that such confusion would 
be found to have occurred in over one-half of the pa-
tients if the required information were available in all 
cases. If the initial manifestation of the disease is easily 
confused with dental infection, evaluation must be made 
of those differentiating features capable of orienting the 
diagnosis towards malignancy, such as chin paresthesia, 
the absence of suppuration, the absence of dental lesions 
justifying an infectious process, the consistency of the 
lesion, possible general patient alterations, etc. - since 
diagnostic and management delays in such aggressive 
tumors can have fatal consequences. Other incorrect ini-
tial diagnostic impressions were altered dental eruption, 
parotitis or benign tumors (Table 1).
In addition to being the most frequent initial manifesta-
tion of the disease, swelling was much more prevalent 
than the second most common manifestation, i.e., pain 
(70.4% versus 28.2%, respectively). An earlier diagno-
sis, and therefore sooner treatment, would contribute to 
avoid the appearance of pain.
The studied publications hardly mentioned the presence 
of metastatic neck adenopathies, which we documented 
in one out of every 10 cases (11.3%).
Ewing sarcoma of the oral cavity was more frequently 
of hard consistency than of elastic or soft consistency 
(29.6% versus 12.7%, respectively). This coincides with 
the observations of Mamede et al., who described the 
tumor as initially being of hard consistency, followed by 
changes in consistency as the lesion gradually destroys 
the cortical layer (32).
Certain clinical features were not as frequent as those 
commented above, but are of special relevance to dental 
surgeons, since these are the professionals most likely to 
be consulted by patients with such manifestations: den-
tal displacement, premature dental exfoliation or loss, 
non-physiological dental mobility, root reabsorption and 
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destruction of the dental follicle. These manifestations 
were recorded in almost one-half of the patients with ES 
of the oral cavity (40.1%). Dental displacement was the 
most frequent alteration, being seen in at least one of 
every 5 cases (19.7%). In the presence of this clinical 
sign, the possibility of a malignant tumor should be con-
sidered, and if the patient is young (5-25 years of age), 
osteosarcoma and Ewing sarcoma must be included in 
the differential diagnosis.
In most cases the overlying oral mucosa was of normal 
appearance, since ES is a mesenchymal tumor that is 
diagnosed relatively early in oral locations - though in at 
least one of every 8 patients (12.7%) the mucosa presen-
ted erythema or ulceration.
Pathological fracture, which is relatively frequent in 
other locations (with an incidence of 15% when the tu-
mor is located in long bones and up to 30% when speci-
fically located at femoral level) (33), is rare in maxillary 
or mandibular tumors (23). In fact, we documented no 
such fractures in the 71 cases compiled in our study.
The radiological features of ES of the oral cavity corres-
pond to a very aggressive, non-osteogenic malignancy. 
The tumor is predominantly radiotransparent, with po-
orly defined limits and no peripheral sclerotic reaction. 
Some sporadic cases have described a radiopaque or 
mixed pattern, with a well defined contour. The sunray 
or onion peel pattern characteristic of malignant bone 
tumors is very infrequent in ES of the oral cavity (34).
Histologically, ES of the oral cavity is currently regar-
ded as a tumor of neuroectodermal origin. Hematoxylin-
eosin (HE) staining reveals an intense blue color that 
defines ES as belonging to the group of small blue round 
cell tumors, along with osteosarcoma, neuroblastoma, 
mesenchymal chondrosarcoma, lymphoma, metastatic 
small-cell lung cancer, rhabdomyosarcoma, synovial 
sarcoma, small round cell desmoplastic tumor, eosino-
philic granuloma and malignant melanoma (35,36).
In turn, the PAS stain (specific of intracytoplasmic 
glycogen granules) is positive in over 90% of these tu-
mors (37) and is useful in differentiating ES from tumors 
of neural lineage, which do not show PAS positivity.
Immunohistochemical techniques detect cluster of diffe-
rentiation 99 (CD99) positivity in up to 98% of these 
tumors (38). Such techniques identify the products deri-
ved from translocation 11:22, but this is also observed in 
lymphoblastic leukemia-lymphoma, Hodgkin and non-
Hodgkin lymphoma, and alveolar and embryonic rhab-
domyosarcoma (35).
The tumor presents a genetic translocation between ge-
nes 11 and 22 (t;11:22) that gives rise to a fusion gene 
(Ewing sarcoma/Friend leukemia integration 1 transcrip-
tion factor [EWS/FLI1]) with potent oncogenic action. 
This gene encodes for a protein that is currently conside-
red to be the main factor responsible for the tumor.
Based on the study of Rosen in 1974 (17), the general 
management strategy for ES comprises initial chemothe-
rapy followed by surgery and, subsequently, radiothera-
py or chemotherapy depending on the initial treatment 
outcome. In the case of non-resectable tumors, treatment 
consists of chemotherapy, radiotherapy and subsequent 
chemotherapy.
As can be seen in Figure 2, this was the management stra-
tegy used in most patients. However, the above treatment 
scheme was not employed in a considerable number of 
cases, either because they predated the Rosen manage-
ment protocol or because of limitations in the treatment 
possibilities (non-accessible tumors, patient refusal to re-
ceive or finance the treatment, etc.). In this regard, Bama-
muth et al. reported that 45% of the patients with ES of 
any location did not receive adequate treatment (39).
Information referred to survival was available in 79.9% 
of the cases. The median survival was 40 months, with 
an apparent difference in median survival between ma-
les and females (36 months versus 48 months). Howe-
ver, the Kaplan-Meier analysis revealed no significant 
gender differences, due to the existence of important va-
riance and wide confidence intervals (Fig. 3).
According to some publications (40), the diagnosis of 
ES requires at least two neuronal markers and evidence 
of translocation 11:22. In order to examine the possibi-
lity that some tumors may have been wrongly classified 
as ES, a survival analysis was performed of the 27 pa-
tients that at least presented HE and PAS positivity and 
CD99-positivity, comparing them with the rest of the ca-
ses based on the Kaplan-Meier method. An evident and 
statistically significant difference in survival was obser-
ved between the two groups (median 24 months; 95%CI 
10.3-37.6 versus 60 months; 95%CI 40.5-79.5 months; 
chi-squared, log-rank test = 8.3; p=0.004), suggesting 
that some cases documented in the literature as ES pro-
bably corresponded to other types of tumors.
The published survival data on ES vary considerably, 
though it is assumed that tumors located in the head and 
neck region have a better prognosis than ES in other lo-
cations (80% versus 56% after three years) (16).
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